Arkolith/Insider Trading/EVLO/Form 4

Flagship Ventures Fund IV-Rx, L.P.

10% OwnerEvelo Biosciences, Inc. (EVLO) · full profile →Form 4 · filed Jun 1, 2022
Net Buying
Open-Market Buys
$40.0M
Open-Market Sells
$0
Net Open-Market Flow
$40.0M
Transactions
5
5 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 27, 2022Buy(P)6.8M$1.46$10.0M8.2M
May 27, 2022Buy(P)1.1M$1.46$1.6M1.9M
May 27, 2022Buy(P)1.4M$1.46$2.0M5.5M
May 27, 2022Buy(P)13.7M$1.46$20.0M13.7M
May 27, 2022Buy(P)4.4M$1.46$6.4M7.6M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-22-020533) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML